TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 18, 2024 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 18, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
April 17, 2024 01:00 ET
|
Sanofi - Aventis Groupe
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting...
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024 16:05 ET
|
Connect Biopharma Holdings Limited
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe...
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:30 ET
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET
|
Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024 08:00 ET
|
Acumen Pharmaceuticals, Inc.
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
April 16, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata...